
Global & China Cancer Therapeutics Market to 2031
Description
China, one of the world’s most populous nations, is experiencing a significant rise in cancer cases, adding to an already substantial health burden. According to the World Health Organization (WHO), approximately 4.5 million new cancer diagnoses and 3 million cancer-related deaths were reported in the country in 2020. Alarming statistics from WHO suggest that, on average, seven individuals are diagnosed with cancer every minute in China, and four die from the disease. The most prevalent cancers include those of the lung, stomach, breast, thyroid, and blood (leukemia).
An important factor contributing to this trend is China’s rapidly aging population. The study Chronic Illness and Ageing in China, published in 2020, forecasts that the share of people aged 60 and older will increase from 12.4% (168 million) in 2010 to 28% (402 million) by 2040. As life expectancy improves, the elderly—who are more vulnerable to cancer—will comprise a larger portion of the population, further driving demand for cancer care.
The growing need for effective cancer therapies has led to advances in treatment, improving survival rates and patient outcomes. Notably, in July 2023, China approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as a standalone treatment for adults with HER2-low metastatic or unresectable breast cancer who had prior systemic therapy or experienced recurrence shortly after adjuvant chemotherapy. Earlier, in January 2022, BeiGene received regulatory approval for its immunotherapy drug Tislelizumab for use as a second- or third-line treatment in patients with advanced or metastatic non-small cell lung cancer. These developments reflect the country’s ongoing commitment to expanding access to innovative cancer therapeutics.
An important factor contributing to this trend is China’s rapidly aging population. The study Chronic Illness and Ageing in China, published in 2020, forecasts that the share of people aged 60 and older will increase from 12.4% (168 million) in 2010 to 28% (402 million) by 2040. As life expectancy improves, the elderly—who are more vulnerable to cancer—will comprise a larger portion of the population, further driving demand for cancer care.
The growing need for effective cancer therapies has led to advances in treatment, improving survival rates and patient outcomes. Notably, in July 2023, China approved AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) as a standalone treatment for adults with HER2-low metastatic or unresectable breast cancer who had prior systemic therapy or experienced recurrence shortly after adjuvant chemotherapy. Earlier, in January 2022, BeiGene received regulatory approval for its immunotherapy drug Tislelizumab for use as a second- or third-line treatment in patients with advanced or metastatic non-small cell lung cancer. These developments reflect the country’s ongoing commitment to expanding access to innovative cancer therapeutics.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. China Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. China Cancer Therapeutics Market – Analysis
- 6.1 China Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 China Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. China Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 China Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. China Cancer Therapeutics Market Analysis – by Indications
- 8.1 China Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. China Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 China Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. China Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. China Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. China Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. China Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. China Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. China Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. China Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. China Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. China Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. China Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.